
Can immunotherapy cause seizures and what to do
Immunotherapy and Seizures: What You Should Know
Immunotherapy can, in rare cases, be linked to neurological side effects such as brain inflammation (encephalitis), which may include seizures. [1] Some immunotherapy drugs list seizures as a serious adverse event that may require stopping treatment. [2] [3] Immune checkpoint inhibitors can cause a spectrum of neurologic immune-related events, and severe cases have been reported, sometimes including seizures. [4] In very uncommon situations, checkpoint inhibitors like nivolumab have been associated with severe brain toxicity that presented with seizures. [5] Seizures are also a recognized part of neurotoxicity with immune effector cell therapies (like CAR T cells), where they are included in formal grading criteria. [6] [7]
How often does this happen?
Most people on immunotherapy do not experience seizures, but neurologic immune-related adverse events do occur in a small percentage, with higher risk when certain therapies are combined. [8] Neurological toxicities with checkpoint inhibitors are considered infrequent but potentially serious, including meningitis, encephalitis, and neuropathies. [9] [10] CAR T–related neurotoxicity (ICANS) more commonly includes confusion, language problems, and sometimes seizures. [11] [12]
Why can immunotherapy trigger seizures?
- Immune activation can inflame the brain or its coverings (encephalitis or meningitis), lowering the seizure threshold. [1]
- Some agents have direct or indirect neurotoxic profiles where seizures are listed among serious adverse events. [2] [3]
- CAR T–related inflammatory cascades and blood–brain barrier changes contribute to neurotoxicity and seizures. [13] [14]
Warning signs to act on
- New or worsening headaches, fever, confusion, memory changes, hallucinations, neck stiffness, or extreme sensitivity to light can be clues to brain inflammation. [1]
- Persistent dizziness, behavior changes, or focal neurologic deficits (like weakness or speech trouble) deserve urgent attention. [15]
- Any first-time seizure or recurrent seizures needs emergency evaluation. [7]
What to do immediately if a seizure occurs
- Ensure safety: protect from injury, turn the person on their side, time the event, and avoid putting anything in the mouth.
- Call emergency services if a seizure lasts more than 5 minutes, repeats without full recovery, or if there is trouble breathing. [7]
- Inform the oncology team promptly, as some therapies may need to be paused and urgent work-up is needed. [2] [3]
Medical evaluation and treatment
- Clinicians will typically check labs, perform brain imaging, and may use EEG to look for ongoing electrical seizures. [7]
- If immune-related brain inflammation is suspected, corticosteroids are commonly used to calm the immune reaction. [4]
- Antiseizure medicines (often levetiracetam) are used for control; benzodiazepines help abort acute seizures. [16] [17]
- In CAR T–related ICANS, care may escalate to ICU-level support, with steroids and sometimes cytokine-targeted agents considered by specialists. [16] [18]
- For high-risk patients receiving immune effector therapies, preventive antiseizure medication can be considered. [19]
Practical coping strategies for users and families
- Keep a simple seizure action plan with emergency steps and key contacts.
- Track symptoms daily (headache, confusion, fevers, sleep changes) and report early changes to the care team. [1]
- Review all medicines with your clinicians to avoid drugs that depress the central nervous system unless needed for seizure care. [18]
- Ensure home safety: avoid heights without supervision, take showers instead of baths, and consider protective measures in living spaces.
- Do not drive until cleared; seizure precautions are important for your safety.
- Ask your team about when to resume therapy and any monitoring (such as imaging) after recovery; decisions are individualized. [2] [3]
Special contexts
- In autoimmune epilepsy, immunotherapy (like high-dose corticosteroids or other agents) is actually used to reduce immune activity and treat seizures, which is a different situation from cancer immunotherapy side effects. [20] [21]
- Antibody therapies for other conditions (for example, anti-amyloid antibodies) can cause imaging changes that sometimes present with seizures, and management may include pausing therapy, steroids, and antiseizure medication. [22]
Quick Reference: Seizures with Immunotherapy
| Scenario | Key features | What clinicians may do |
|---|---|---|
| Checkpoint inhibitor neurologic irAEs | Headache, fever, confusion, encephalitis; seizures can occur | Urgent evaluation, corticosteroids, antiseizure meds; consider pausing drug |
| CAR T–related ICANS | Confusion, aphasia, somnolence; seizures; may follow cytokine release syndrome | Grading with ICE/CTCAE; ICU care for severe cases; steroids, seizure control; selective cytokine modulation |
| Specific drug labeling with “seizures” | Product information lists seizures as serious events | Withhold or discontinue, investigate cause, manage neurologic toxicity |
When to call your team
- Any first seizure or prolonged/repeated seizure. [7]
- New neurologic symptoms (persistent headache, high fever with confusion, neck stiffness, unusual behavior, focal weakness). [1] [15]
- Worsening drowsiness or difficulty being aroused. [7]
Outlook
While seizures related to immunotherapy are uncommon, prompt recognition and treatment often lead to recovery, and therapy plans can be adjusted safely by your oncology team. [8] Early communication and a clear action plan help you stay safe and continue treatment when appropriate. [18]
Related Questions
Sources
- 1.^abcdefManaging Your Immunotherapy Side Effects(mskcc.org)
- 2.^abcdePROLEUKIN- aldesleukin injection, powder, lyophilized, for solution(dailymed.nlm.nih.gov)
- 3.^abcdePROLEUKIN- aldesleukin injection, powder, lyophilized, for solution(dailymed.nlm.nih.gov)
- 4.^abcNeurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy.(pubmed.ncbi.nlm.nih.gov)
- 5.^abFatal Necrotizing Encephalopathy after Treatment with Nivolumab for Squamous Non-Small Cell Lung Cancer: Case Report and Review of the Literature.(pubmed.ncbi.nlm.nih.gov)
- 6.^abImmune effector cell associated-neurotoxicity syndrome (ICANS)(eviq.org.au)
- 7.^abcdefImmune effector cell associated-neurotoxicity syndrome (ICANS)(eviq.org.au)
- 8.^abResearch highlights in Neurology and Neurosurgery ― September 2019(mayoclinic.org)
- 9.^↑3840-Advanced, metastatic or recurrent pembrolizumab(eviq.org.au)
- 10.^↑4108-Gastroesophageal and oesophageal adjuvant nivolumab(eviq.org.au)
- 11.^↑Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies.(pubmed.ncbi.nlm.nih.gov)
- 12.^↑Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.(pubmed.ncbi.nlm.nih.gov)
- 13.^abCytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies.(pubmed.ncbi.nlm.nih.gov)
- 14.^abCytokines in CAR T Cell-Associated Neurotoxicity.(pubmed.ncbi.nlm.nih.gov)
- 15.^abManaging Your Immunotherapy Side Effects(mskcc.org)
- 16.^abc3834-Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)(eviq.org.au)
- 17.^↑3834-Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)(eviq.org.au)
- 18.^abc3834-Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)(eviq.org.au)
- 19.^↑3834-Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)(eviq.org.au)
- 20.^↑Autoimmune epilepsy - Diagnosis and treatment(mayoclinic.org)
- 21.^↑Autoimmune epilepsy - Diagnosis and treatment(mayoclinic.org)
- 22.^↑Amyloid-Related Imaging Abnormalities With Anti-amyloid Antibodies for the Treatment of Dementia Due to Alzheimer's Disease.(pubmed.ncbi.nlm.nih.gov)
Important Notice: This information is provided for educational purposes only and is not intended to replace professional medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider before making any medical decisions.


